About Careers Internship MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Drug Alternative Childhood Leukemia Chemo Developed

by Tanya Thomas on August 1, 2009 at 10:05 AM
Font : A-A+

 Drug Alternative Childhood Leukemia Chemo Developed

A drug which may prove to be an alternative to traumatic chemotherapy for childhood leukaemia has been developed by scientists from Tel Aviv University.

"Modern medicine can cure eight out of 10 cases of childhood leukemia, so parents can still be hopeful when they hear a diagnosis," the Lancet quoted Dr Shai Izraeli of Tel Aviv University's Sackler School of Medicine and Sheba Medical Centre.

Advertisement

"Our research gives hope and life to the 20pct who might not make it as well as those who may experience a relapse," Izraeli added.

The research team led by Izraeli has previously identified a protein called JAK 2 in Down Syndrome patients, which can also play a role in other disorders and diseases.
Advertisement

Based on the results, the researchers believe that a drug that is already in clinical trials for a blood disease common in adults may work for acute childhood leukemia.

If initial trials go well, they say that, it could fast track through approvals and could be available for treating children with leukemia in only a few years.

According to Izraeli, a similar mutation of the JAK2 in Down syndrome and leukemia causes Polycythemia Vera, a disease common in adults that leads to the overproduction of blood.

This discovery might provide a path to new life-saving medication.

A child with Down syndrome is 20 to 30 times more likely to develop leukemia during childhood than a child without it).

Izraeli had first discovered JAK2 mutations in children who initially suffered from Down syndrome and subsequently developed leukaemia. He later screened gene mutations that could result in increased proliferation of cells.

"This is perhaps the first example of two very similar - but different - mutations that apparently do the same thing in a cellular protein. But they're associated with two completely different disorders, one that causes polycythemia in adults and the other that causes leukemia in children," said Izraeli.

"Those children at the highest risk for leukemia may be treated with inhibitors of JAK2.

"And because of the existence of polycythemia in adults, there are already drugs to fight polycythemia entering into trials as we speak.

We will know in just a few years what these drugs are capable of," he added.

Source: ANI
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Alarming Cesarean Section Trends in India - Convenience or Compulsion of Corporate Healthcare
Quiz on Low-Calorie Diet for Diabetes
World Heart Day in 2022- Use Heart for Every Heart
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity Leukemia Chronic Myeloid Leukemia Acute Myeloid Leukemia Acute Lymphoblastic Leukemia Signature Drug Toxicity Multiple Myeloma Bone Marrow Transplantation Hairy Cell Leukemia Childhood Cancer 

Most Popular on Medindia

Pregnancy Confirmation Calculator Turmeric Powder - Health Benefits, Uses & Side Effects Indian Medical Journals Selfie Addiction Calculator Iron Intake Calculator Blood - Sugar Chart A-Z Drug Brands in India Post-Nasal Drip Noscaphene (Noscapine) Vent Forte (Theophylline)
This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
×

Drug Alternative Childhood Leukemia Chemo Developed Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests